Sublingual allergen immunotherapy in children: An evidence-based overview

Revue Francaise d'Allergologie

Volumn 52, Issue 1, 2012, Pages 20-25

  Calderon M A ^a   Rodriguez del Rio, P ^b   Demoly, P ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Allergic rhinitis; Asthma; Children; Sublingual immunotherapy

Indexed keywords

ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 5;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; BEE STING; CONJUNCTIVITIS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EPIPHORA; EVIDENCE BASED MEDICINE; FOOD ALLERGY; HOUSE DUST ALLERGY; HUMAN; LONG TERM CARE; MAINTENANCE DRUG DOSE; OCULAR PRURITUS; PEANUT ALLERGY; POPULATION; REVIEW; SAFETY; SENSITIZATION; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION;

EID: 84856223998     PISSN: 18770320     EISSN: 18770312     Source Type: Journal    
DOI: 10.1016/j.reval.2011.11.002     Document Type: Review

References (48)

1. Noon L. Prophylactic inoculations against hay fever. Lancet 1911, 1:1572-1573.
2. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011, 66(6):740-752.
3. Calderón M.A., Casale T.B., Togias A., Bousquet J., Durham S.R., Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011, 127(1):30-38. [Epub 2010 Oct 20].
4. Wahn U., Tabar A., Kuna P., Halken S., Montagut A., de Beaumont O., et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009, 123:160-166.
5. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009, 123:16-173.
6. Blaiss M., Maloney J., Nolte H., Gawchik S., Yao R., Skoner D.P. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011, 127(1):64-71.
7. Calderón M.A., Larenas D., Kleine-Tebbe J., et al. European Academy of Allergy and Clinical Immunology task force report on "dose-response relationship in allergen-specific immunotherapy" Allergy. 2011, 66(10):1345-1359.
8. Valovirta E., Jacobsen L., Ljorring C., Koivikko A., Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177-1183.
9. Roder E., Berger M.Y., Hop W.C., Bernsen R.M., de Groot H., Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007, 119:892-898.
10. Warner J., Price J.F., Soothill J.F., Hey E.N. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978, 2:912-915.
11. Penagos M., Passalacqua G., Compalati E., et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008, 133:599-609.
12. Pajno G.B., Morabito L., Barberio G., Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy. 2000, 55(9):842-849.
13. Cox L. Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007, 7:410-420.
14. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998, 102(4 Pt 1):558-562.
15. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008, 63(Suppl. 86):8-160.
16. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206-210.
17. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
18. Durham S.R. GT-08 investigators. Allergy. 2011, 66(Suppl. 95):50-52. [Sustained effects of grass pollen AIT].
19. Bufe A., Roberts G. Specific immunotherapy in children. Clin Exp Allergy. 2011, 41(9):1256-1262.
20. GAP Study: Grazax Asthma Prevention http://clinicaltrials.gov/ct2/show/NCT01061203.
21. Passalacqua G., Guerra L., Compalati E., Canonica G.W. The safety of allergen specific sublingual immunotherapy. Curr Drug Saf 2007, 2:117-123.
22. Radulovic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010, (12):CD002893. Review.
23. Penagos M., Compalati E., Tarantini F., et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006, 97:141-148.
24. Ibañez M.D., Kaiser F., Knecht R., et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007, 18:516-522.
25. Antico A., Pagani M., Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006, 61:1236-1237.
26. Dunsky E.H., Goldstein M.F., Dvorin D.J., Belecanech G.A. Anaphylaxis to sublingual immunotherapy. Allergy 2006, 61:1235.
27. Eifan A.O., Keles S., Bahceciler N.N., Barlan I.B. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007, 62:567-568.
28. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008, 63:374.
29. de Groot H., Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009, 64:963-964.
30. Buyukozturk S., Gelincik A., Ozşeker F., Colakoĝlu B., Dal M. Latex sublingual immunotherapy: can its safety be predicted?. Ann Allergy Asthma Immunol. 2010, 104:339-342.
31. Rodríguez-Pérez N., Ambriz-Moreno M.J., Canonica G.W., Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol. 2008, 101:304-310.
32. Nelson H.S., Lahr J., Rule R., Bock A., Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997, 99(6):744-751.
33. Enrique E., Pineda F., Malek T., et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005, 116:1073-1079.
34. Fernandez-Rivas M., Garrido Fernandez S., Nadal J.A., et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009, 64:876-883.
35. Kim E.H., Bird J.A., Kulis M., et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011, 127(3):640-646.
36. FAST: http://www.allergome.org:8080/fast/index.jsp.
37. Calderon M.A., Penagos M., Sheikh A., Canonica G.W., Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev 2011, (7):CD007685. Review.
38. Park J.H., Choi Y.L., Namkung J.H., et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006, 155:778-783.
39. Schäfer T. The impact of allergy on atopic eczema from data from epidemiological studies. Curr Opin Allergy Clin Immunol. 2008, 8(5):418-422.
40. Pajno G.B., Caminiti L., Vita D., et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007, 120:164-170.
41. Nettis E., Colanardi M.C., Soccio A.L., et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007, 156:674-681.
42. Bernardini R., Compodonico P., Burastero S., et al. Sublingual immunotherapy with a latex extract in paediatric patients: a doublé-blind, placebo-controlled study. Curr Med Res Opin. 2006, 22(8):1515-1522.
43. Bonifazi F., Jutel M., Bilò M.B., Birnbaum J., Muller U. the EAACI Interest Group on insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005, 60:1459-1470.
44. Severino M.G., Cortellini G., Bonadonna P. Sublingual immunotherapy for large local reactions caused by honeybee sting: a double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2008, 122(1):44-48.
45. Scadding G., Durham S.R. Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am. 2011, 31(2):191-209.
46. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., Ebner C. Sublingual immunotherapy induces IL-10-producing T-regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007, 120:707-713.
47. Allam J.P., Stojanovski G., Friedrichs N., et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of Allergens in sublingual immunotherapy?. Allergy 2008, 63:720-727.
48. Novak N., Haberstok N., Bieber T., Allam J.P. The immune privilege of the oral mucosa. Trends Mol Med. 2008, 14(5):191-198.